First Hawaiian Bank’s Allogene Therapeutics ALLO Stock Holding History

First Hawaiian Bank’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,260	Closed	-$243K	–	914
2021 Q4	$243K	Hold	16,260	–	–	0.01%	840
2021 Q3	$418K	Hold	16,260	–	–	0.02%	582
2021 Q2	$424K	Buy	16,260 +4,850	+43%	+$138K	0.02%	591
2021 Q1	$403K	Hold	11,410	–	–	0.02%	614
2020 Q4	$288K	Hold	11,410	–	–	0.01%	671
2020 Q3	$430K	Buy	+11,410	New	+$430K	0.02%	475

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

First Hawaiian Bank's ALLO Position: Q1 2022 in Review

First Hawaiian Bank sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 16,260 shares — an estimated $243K sold.

First Hawaiian Bank first reported a position in ALLO in Q3 2020 and held it in 6 quarters. The position peaked at $430K in Q3 2020. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

First Hawaiian Bank reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
First Hawaiian Bank sold 16,260 Allogene Therapeutics shares in Q1 2022, an estimated $243K.
First Hawaiian Bank first reported a position in Allogene Therapeutics in Q3 2020 and held it in 6 quarters.
First Hawaiian Bank's Allogene Therapeutics position peaked at $430K in Q3 2020.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on First Hawaiian Bank's 13F filing for Q1 2022, filed 6 Apr 2022.